CASI Pharmaceuticals, Inc.
corporate_fare Company Profile
CASI Pharmaceuticals, Inc. (OTC:CASIF) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 6 items for CASIF at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-02, rated 8/10. Across its 6 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for CASIF spans 6-K, SCHEDULE 13D/A, 20-F.
Recent high-impact activity:
- CASI Sells Alesta Stake to BioMarin for $5.9M Net Cash
- CASI Reports H1 2026: $20M Loss, $3.8M Cash, Going Concern Warning
- CASI Secures Arbitration Victory: Juventas Wrongfully Terminated CNCT-19 Deal, Over RMB 100M Awarded
- CASI Pharmaceuticals Settles Arbitration, Retains Evomela® License in China
- CASI Pharma Secures $5M Convertible Note Financing Amid Delisting & Going Concern
Financial Snapshot
Short Interest & Short Volume
32.83 days to coverFINRA reported short interest of 144,431 shares in CASIF as of the October 30, 2026 settlement, unchanged from the prior period — about 32.8 days to cover at its recent average daily volume. On November 20, 2026, 67.6% of CASIF volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
CASIF files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.